Dec. 12, 2025—Natera has completed a transaction to acquire cancer diagnostics company Foresight Diagnostics. The transaction combines Natera’s commercial and operational infrastructure for the delivery of personalized molecular residual disease testing with Foresight’s phased variant technology and focus on lymphoma testing. Foresight’s circulating tumor DNA–based MRD tests leverage its patented PhasED-Seq technology, targeting phased variants.
“This acquisition reinforces Natera’s position at the forefront of precision oncology,” Steve Chapman, chief executive officer of Natera, said in a press statement. “Foresight’s phased variant technology and leadership in lymphoma complement Natera’s strong capabilities in personalized MRD testing, improving the value we can deliver to patients, clinicians, biopharma partners, and the broader health care system.”
Natera has closed the acquisition of Foresight in an all-stock transaction consisting of a $275 million up-front with an additional $175 million in earn-outs tied to the achievement of revenue- and reimbursement-based milestones.